Cedric Francois Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Cedric Francois is Chief Executive Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 313,662 shares of APLS, which is worth approximately $10.4 Million. The most recent transaction as insider was on Mar 01, 2024, when has been sold 250,000 shares (Common Stock) at a price of $64.01 per share, resulting in proceeds of $16,002,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 314K

0% 3M change

16.32% 12M change

Total Value Held $10.4 Million

Cedric Francois Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 01 2024	SELL Open market or private sale	$16,002,500 $64.01 p/Share	250,000 Reduced 44.35%	313,662 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$1,010,000 $4.04 p/Share	250,000 Added 30.73%	563,662 Common Stock
Feb 12 2024	SELL Open market or private sale	$268,504 $67.77 p/Share	3,962 Reduced 1.25%	313,662 Common Stock
Jan 29 2024	SELL Open market or private sale	$182,350 $64.14 p/Share	2,843 Reduced 0.89%	317,624 Common Stock
Jan 22 2024	SELL Open market or private sale	$873,015 $65.0 p/Share	13,431 Reduced 4.02%	320,467 Common Stock
Jan 16 2024	SELL Open market or private sale	$524,525 $66.81 p/Share	7,851 Reduced 2.3%	333,898 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	72,094 Added 17.42%	341,749 Common Stock
Nov 21 2023	SELL Open market or private sale	$244,000 $48.8 p/Share	5,000 Reduced 1.82%	269,655 Common Stock
Sep 19 2023	SELL Bona fide gift	-	150,000 Reduced 35.32%	274,655 Common Stock
Sep 01 2023	SELL Open market or private sale	$6,310,500 $42.07 p/Share	150,000 Reduced 26.1%	424,655 Common Stock
Sep 01 2023	BUY Exercise of conversion of derivative security	$801,000 $2.67 p/Share	300,000 Added 34.3%	574,655 Common Stock
May 24 2023	SELL Bona fide gift	-	20,000 Reduced 6.79%	274,655 Common Stock
May 17 2023	BUY Exercise of conversion of derivative security	$53,400 $2.67 p/Share	20,000 Added 6.36%	294,655 Common Stock
May 16 2023	SELL Open market or private sale	$2,562,900 $85.43 p/Share	30,000 Reduced 9.85%	274,655 Common Stock
May 16 2023	BUY Exercise of conversion of derivative security	$80,100 $2.67 p/Share	30,000 Added 8.96%	304,655 Common Stock
Apr 27 2023	SELL Bona fide gift	-	382,946 Reduced 58.23%	274,655 Common Stock
Apr 19 2023	BUY Exercise of conversion of derivative security	$53,400 $2.67 p/Share	20,000 Added 2.95%	657,601 Common Stock
Apr 18 2023	SELL Open market or private sale	$2,460,600 $82.02 p/Share	30,000 Reduced 4.49%	637,601 Common Stock
Apr 18 2023	BUY Exercise of conversion of derivative security	$80,100 $2.67 p/Share	30,000 Added 4.3%	667,601 Common Stock
Apr 05 2023	SELL Bona fide gift	-	26,990 Reduced 4.06%	637,601 Common Stock
Apr 04 2023	SELL Bona fide gift	-	380,000 Reduced 36.38%	664,591 Common Stock
Apr 03 2023	SELL Bona fide gift	-	227,221 Reduced 17.87%	1,044,591 Common Stock
Mar 22 2023	BUY Exercise of conversion of derivative security	$860,013 $6.76 p/Share	127,221 Added 9.09%	1,271,812 Common Stock
Mar 21 2023	SELL Open market or private sale	$1,882,200 $62.74 p/Share	30,000 Reduced 2.55%	1,144,591 Common Stock
Mar 21 2023	BUY Exercise of conversion of derivative security	$80,100 $2.67 p/Share	30,000 Added 2.49%	1,174,591 Common Stock

Cedric Francois

Chief Executive Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account